search
Back to results

Change of Renal Function and Bone Mineral Density in CHB Patients Switch From TDF to TAF vs. Maintaining TDF (SWITAF)

Primary Purpose

Chronic Hepatitis B

Status
Recruiting
Phase
Phase 4
Locations
Hong Kong
Study Type
Interventional
Intervention
Tenofovir alafenamide(TAF)
Tenofovir disoproxil fumarate(TDF)
Sponsored by
Humanity and Health Research Centre
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Hepatitis B focused on measuring Chronic hepatitis B, Efficacy, safety, and tolerability, Tenofovir alafenamide

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Chronic hepatitis B,
  2. Antiviral experienced,
  3. Currently on long term TDF anti-HBV treatment,
  4. HBV DNA < 6 log IU/ml (LLOD)
  5. Able to sign the consent form of anticipating in the study

Exclusion Criteria:

  1. Co-infected with HCV, HIV or other viral hepatitis,
  2. Diagnosis of HCC

Sites / Locations

  • Humanity and Health GI and Liver CentreRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

TDF switch to TAF

Maintaining on TDF

Arm Description

Tenofovir Disoproxil Fumarate(TDF) 300mg daily switch to Tenofovir Alafenamide(TAF) 25mg daily

Maintaining on Tenofovir Disoproxil Fumarate(TDF) 300mg daily

Outcomes

Primary Outcome Measures

Antiviral response of TAF
Anti-HBV effectiveness of TAF compared with TDF in treatment experienced CHB patients

Secondary Outcome Measures

Improvement of renal function and bone mineral density in CHB patients switching to TAF
Change of renal function and bone mineral density from baseline in CHB patients of TAF a group compared with TDF group

Full Information

First Posted
September 20, 2017
Last Updated
December 19, 2022
Sponsor
Humanity and Health Research Centre
search

1. Study Identification

Unique Protocol Identification Number
NCT03356834
Brief Title
Change of Renal Function and Bone Mineral Density in CHB Patients Switch From TDF to TAF vs. Maintaining TDF
Acronym
SWITAF
Official Title
Change of Renal Function and Bone Mineral Density Marker in Chronic Hepatitis B Patients Switching From TDF to TAF vs. Maintaining TDF
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
December 1, 2017 (Actual)
Primary Completion Date
October 2023 (Anticipated)
Study Completion Date
October 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Humanity and Health Research Centre

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
In Chronic hepatitis B (CHB) patients receiving long-term sequential Neucleos(t)ides(NAs), majority of these CHB patients experienced drug resistance and switched to Tenofovir disoproxil fumaratate(TDF). However, some of patients on long term TDF experienced impairment of renal function and bone mineral density. After Tenofovir alafenamide(TAF) was in clinical practice, these group of patients got an clinical option to switch from TDF to TAF. The investigators designed a prospective cohort study to evaluate the real life effectiveness and safety in participants with chronic HBV infection switch from TDF to TAF vs. maintaining on TDF.
Detailed Description
Tenofovir disoproxil fumarate(TDF) have been associated with renal toxicity and reduced bone mineral density. Tenofovir alafenamide(TAF) is a novel tenofovir prodrug that reduces tenofovir plasma concentrations by 90%, thereby decreasing off-target side-effects. The investigators aimed to assess whether efficacy, safety, and tolerability were non-inferior in participants switched to TAF versus in those remaining on TDF. This is a prospective clinical study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Hepatitis B
Keywords
Chronic hepatitis B, Efficacy, safety, and tolerability, Tenofovir alafenamide

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
1000 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
TDF switch to TAF
Arm Type
Experimental
Arm Description
Tenofovir Disoproxil Fumarate(TDF) 300mg daily switch to Tenofovir Alafenamide(TAF) 25mg daily
Arm Title
Maintaining on TDF
Arm Type
Active Comparator
Arm Description
Maintaining on Tenofovir Disoproxil Fumarate(TDF) 300mg daily
Intervention Type
Drug
Intervention Name(s)
Tenofovir alafenamide(TAF)
Other Intervention Name(s)
VEMLIDY®
Intervention Description
25 mg tablet administered orally once daily
Intervention Type
Drug
Intervention Name(s)
Tenofovir disoproxil fumarate(TDF)
Other Intervention Name(s)
VIREAD®
Intervention Description
300 mg tablet administered orally once daily
Primary Outcome Measure Information:
Title
Antiviral response of TAF
Description
Anti-HBV effectiveness of TAF compared with TDF in treatment experienced CHB patients
Time Frame
60 months
Secondary Outcome Measure Information:
Title
Improvement of renal function and bone mineral density in CHB patients switching to TAF
Description
Change of renal function and bone mineral density from baseline in CHB patients of TAF a group compared with TDF group
Time Frame
60 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Chronic hepatitis B, Antiviral experienced, Currently on long term TDF anti-HBV treatment, HBV DNA < 6 log IU/ml (LLOD) Able to sign the consent form of anticipating in the study Exclusion Criteria: Co-infected with HCV, HIV or other viral hepatitis, Diagnosis of HCC
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Cheng Wang, M.D. PhD
Phone
21539831
Email
wangcheng@hnhmgl.com
First Name & Middle Initial & Last Name or Official Title & Degree
Yudong Wang, PhD
Phone
21539831
Email
dannywang@hnhmgl.com
Facility Information:
Facility Name
Humanity and Health GI and Liver Centre
City
Hong Kong
ZIP/Postal Code
00852
Country
Hong Kong
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
George KK Lau, MD
Phone
(852)28613777
Email
gkklau@netvigator.com
First Name & Middle Initial & Last Name & Degree
Cheng Wang, M.D, PhD
Phone
21539831
Email
wangcheng@hnhmgl.com
First Name & Middle Initial & Last Name & Degree
George KK Lau, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Change of Renal Function and Bone Mineral Density in CHB Patients Switch From TDF to TAF vs. Maintaining TDF

We'll reach out to this number within 24 hrs